PROVIDER**ALERT**



To: AmeriHealth Caritas Louisiana Providers

Date: July 17, 2023

Subject: ADHD Follow-Up Care after Medication Administration

Summary: AmeriHealth Caritas Louisiana is providing Best Practice follow-up recommendations for members newly prescribed an ADHD medication.

Recommendation: At least three follow-up care visits within a 10-month period, one of which must be within 30 days, Initiation Phase, of when the first ADHD medication was dispensed.

There are two phases for ADHD follow-up visits for medication compliance:

- **1. Initiation phase:** Patients should receive one follow-up visit with a practitioner with prescribing authority during the 30 days following the earliest prescription dispensing date.
- **2.** Continuation phase: Patients who remained on the medication for at least 210 days, and had a follow-up visit in the initiation phase should receive at least two follow-up visits within 270 days after the initiation phase ended.

Start Here	Month	Month	Month	Month	Month	Month	Month	Month	Month	Month
	1	2	3	4	5	6	7	8	9	10
Medication Dispensed	Follow- up Visit #1	•		Follow-up Visit #2		→ ←		Follow-up Visit #3]	

Timeline for ADHD Follow-up Visits

Note: If a patient has not filled a prescription in three months, the timeline for ADHD Follow-up Visits should restart.

Best Practices:

- Assist member with scheduling follow-up visits when newly prescribed an ADHD medication
- If needed, utilize telephone and telehealth visits in both the Initiation and Continuation Phases. Only one of the two Continuation Phase visits can be an e-visit or virtual check-in.
- According to AAP, American Academy of Pediatrics, Behavioral therapy has positive effects when combined with medication for ADHD.
 - Children under six (6) years old should receive behavioral health therapy and/or behavioral classroom interventions as the first line of treatment before administration of medications for best practice.

- Children and adolescents (6-12) should receive both FDA, US Food and Drug Administration, ADHD medication and behavioral therapy, and/or behavioral classroom intervention, if possible.
- Adolescents (12-18th birthday) should receive FDA-approved medications for ADHD and provider should also prescribe evidence-based training interventions and/or behavioral interventions as treatment of ADHD, if available.

Resources:

- This information can also be collected through Electronic Clinical Data Systems. Direct data feeds can improve provider quality performance and reduce the burden of medical record requests. Please discuss options with your Account Executive.
- Access ADHD Toolkit: Resource Toolkit for Clinicians brings AAP, American Academy of Pediatrics, recommendations to your practice. It provides a full set of ready-to-use tools many in Spanish and English. Check the ACLA Provider Portal under Resources >then Handbooks and Guides.

Reference:

American Academy of Pediatrics. SUBCOMMITTEE ON CHILDREN AND ADOLESCENTS WITH ATTENTION-DEFICIT/HYPERACTIVE DISORDER. Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents. Pediatrics. 2019;Volume 144, Issue 4

Questions: Thank you for your continued support and commitment to the care of our members. If you have questions about this communication, please contact AmeriHealth Caritas Louisiana Provider Services at 1-888-922-0007 or your <u>Provider Network Management Account Executive</u>.

Missed an alert?

You can find a complete listing of provider alerts on the <u>Provider Newsletters and Updates</u> page of our website.

Where can I find more information on COVID-19?

AmeriHealth Caritas Louisiana has updated its website to streamline communications and important notifications about COVID-19. Please visit <u>http://amerihealthcaritasla.com/covid-19</u> for up-to-date information for both providers and members, including frequently asked questions, and important provider alerts from AmeriHealth Caritas Louisiana and the Louisiana Department of Health.